Valuation: AbbVie Inc.

Capitalization 346B 333B 313B 276B 493B 30,109B 546B 3,726B 1,391B 12,575B 1,299B 1,273B 52,530B P/E ratio 2025 *
26.4x
P/E ratio 2026 * 21.8x
Enterprise value 399B 383B 361B 317B 567B 34,668B 629B 4,290B 1,601B 14,479B 1,496B 1,465B 60,483B EV / Sales 2025 *
6.72x
EV / Sales 2026 * 6.08x
Free-Float
96.39%
Yield 2025 *
3.32%
Yield 2026 * 3.47%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.62%
1 week+2.88%
Current month+7.31%
1 month+15.03%
3 months+18.69%
6 months+1.78%
Current year+11.06%
More quotes
1 week
190.67
Extreme 190.6683
198.11
1 month
168.06
Extreme 168.06
198.11
Current year
168.06
Extreme 168.06
198.11
1 year
153.58
Extreme 153.58
207.32
3 years
130.96
Extreme 130.9601
207.32
5 years
62.55
Extreme 62.55
207.32
10 years
45.45
Extreme 45.45
207.32
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2024
Director of Finance/CFO 58 23/06/2022
Chief Tech/Sci/R&D Officer - 01/01/2003
Director TitleAgeSince
Chairman 71 01/01/2013
Director/Board Member 64 01/01/2013
Director/Board Member 73 01/01/2013
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+0.56%+2.88%+11.19%+37.02% 346B
+1.15%+0.24%+10.87%+260.80% 772B
+1.87%+1.13%+0.86%-3.35% 373B
+1.79%-0.45%-29.78%+80.57% 366B
-0.07%+2.26%+29.14%-13.97% 263B
-0.71%+0.69%+15.95%+32.98% 231B
+2.77%-1.09%-33.02%+12.09% 211B
+0.44%-1.48%+9.22%+20.99% 211B
+0.50%-0.81%+3.73%+33.29% 157B
+1.29%+1.41%-6.26%-46.65% 145B
Average +0.87%-0.47%+1.19%+41.38% 307.37B
Weighted average by Cap. +0.96%-0.46%+2.50%+81.89%
See all sector performances

Financials

2025 *2026 *
Net sales 59.35B 57.03B 53.71B 47.21B 84.43B 5,158B 93.58B 638B 238B 2,154B 223B 218B 8,999B 63.95B 61.45B 57.87B 50.86B 90.96B 5,558B 101B 688B 257B 2,321B 240B 235B 9,696B
Net income 11.88B 11.42B 10.75B 9.45B 16.91B 1,033B 18.74B 128B 47.7B 431B 44.55B 43.65B 1,802B 14.84B 14.26B 13.43B 11.8B 21.11B 1,290B 23.4B 160B 59.57B 539B 55.64B 54.51B 2,250B
Net Debt 52.46B 50.41B 47.47B 41.72B 74.62B 4,559B 82.71B 564B 211B 1,904B 197B 193B 7,954B 42.53B 40.87B 38.49B 33.83B 60.5B 3,697B 67.06B 457B 171B 1,544B 159B 156B 6,449B
More financial data * Estimated data
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).
Employees
55,000
More about the company
Date Price Change Volume
20/02/25 197.35 $ +0.56% 4,887,984
18/02/25 196.25 $ +1.75% 6,065,546
14/02/25 192.87 $ -0.30% 3,976,903
13/02/25 193.45 $ +0.23% 4,108,920
12/02/25 193.00 $ +0.61% 4,525,009

Delayed Quote Nyse, 20 February 2025 at 08:00 am AEDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
196.25USD
Average target price
204.90USD
Spread / Average Target
+4.41%
Consensus

Quarterly revenue - Rate of surprise